[AF] Nuevo número del WHO Pharmaceuticals Newsletter: No.4, 2004

[Martín Cañás]

Esta disponible en la red el WHO Pharmaceuticals Newsletter no 4 del 2004

La dirección es:
http://www.who.int/medicines/library/pnewslet/4news2004.pdf

y el índice:

REGULATORY MATTERS
ALOSETRON - Risk management plan to remain in place 1
ANTIDEPRESSANTS - Health Canada-endorsed safety information 1
BUPROPION - Labelling updated to include class warning 1
CLOZAPINE - Labelling to include updated patient safety registry information
1
DEXTROPROPOXYPHENE/PARACETAMOL - Prescribing reminder 2
DOMPERIDONE - Not to be used to increase milk production in women 2
LEFLUNOMIDE - Update on interstitial lung disease 2
ROSUVASTATIN - Higher dose and predisposing factors linked with
rhabdomyolysis 3
SULPHUR HEXAFLUORIDE - Use in echocardiography suspended 3

SAFETY OF MEDICINES
ATYPICAL ANTIPSYCHOTICS - Reports of diabetes 4
ATYPICAL ANTIPSYCHOTICS - ADR update from Finland 4
BISPHOSPHONATES - Reports of ocular disorders 5
DIETHYLSTILBESTROL - Still causing problems decades later 5
MERCAPTAMINE, MERCAPTOPURINE - Medication errors due to name confusion 5
METHADONE - Risk of QT prolongation 5
PARECOXIB - Associated with renal impairment 6
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) - Potential risks of in
utero exposure 6
TESTOSTERONE - Not to be used as a cure for impotence 6
THERMONEX - Health Canada advises against use 6
TNF-  ANTAGONIST - Treatment associated with tuberculosis 6
TRAZODONE - Interaction with certain medications 7
WARFARIN - Interactions with macrolides 7

ANNOUNCEMENT 8

Saludos,

Martin